Sermorelin vs Tesamorelin

How they're alike

Sermorelin and tesamorelin are both synthetic analogs of human growth hormone-releasing hormone (GHRH) and both act as agonists at the GHRH receptor on anterior-pituitary somatotrophs, where receptor engagement triggers the cAMP/PKA cascade and drives pulsatile growth-hormone secretion, with downstream IGF-1 elevation through the liver. Their sequences share the same N-terminal scaffold: a local alignment of the two peptides is 100% identical over the 30-residue overlap, so the GHRH-receptor binding pharmacophore is essentially common between them. Both trace back to the early GHRH characterization work of the 1980s, when N-terminal fragments and analogs of the native hypothalamic peptide were systematically synthesized and bioassayed for somatotroph activity (Ling 1984; Gelato 1985), and both belong to the broader teleost-and-mammalian GHRH family whose evolutionary primary structure was mapped through comparative work such as the carp GRF isolation (Vaughan 1992) — the single reference cited in both cards' reference sets. Both are also classified by WADA as Prohibited at all times under category S2 (peptide hormones, growth factors, related substances, and mimetics), regardless of regulatory approval status in any individual jurisdiction.

How they differ

The two peptides differ at three connected levels: length, chemical stability, and regulatory standing. Sermorelin is the bare 29-residue N-terminal fragment of GHRH — historically the shortest portion of the 44-residue native peptide shown to retain full receptor activity (Ling 1984) — and is C-terminally amidated. Tesamorelin, in contrast, retains the entire 44-residue GHRH backbone but adds a trans-3-hexenoyl group at the N-terminal tyrosine; this acyl modification sterically blocks cleavage by dipeptidyl peptidase IV (DPP-IV) while preserving full agonist activity at the GHRH receptor. The pharmacokinetic consequence is large: sermorelin's plasma half-life is on the order of ~6 minutes by the intravenous route, so each subcutaneous dose produces a single transient GH pulse before the peptide is degraded, whereas tesamorelin's DPP-IV-protected backbone extends the subcutaneous half-life to roughly 26–38 minutes, which is what makes a once-daily dosing schedule clinically viable for a chronic indication.

The regulatory trajectories diverged accordingly. Sermorelin (as Geref) was FDA-approved in 1990 for diagnostic use in pituitary GH-reserve testing and in 1997 for pediatric idiopathic growth-hormone deficiency, but the brand product was voluntarily withdrawn from the US market in 2008 for commercial — not safety or efficacy — reasons, and the NDA approvals were formally withdrawn in 2009. In the US sermorelin is now available only through state-licensed compounding pharmacies, where it is prescribed off-label for adult body-composition, sleep, and anti-aging indications that were never part of the original label, and where dedicated adult-onset GHD efficacy RCTs have not been performed (Walker 2006). Tesamorelin (as Egrifta) was FDA-approved in November 2010 for a single, narrow indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It remains the only GHRH analog currently holding a full FDA approval. A small literature also positions both peptides within the broader landscape of growth-hormone secretagogues used off-label for body-composition endpoints in hypogonadal and aging men, but with the explicit caveat that controlled adult-population evidence is limited (Sinha 2020), and one exploratory line of work has examined sermorelin for oncology indications outside its historical label (Chang 2021).

Head-to-head clinical evidence

No head-to-head randomized controlled trial directly comparing sermorelin and tesamorelin against each other was identified in this dossier — the PubMed search for papers naming both peptides in their titles returned zero results, and neither card's reference set contains a head-to-head trial. Each peptide's controlled evidence base sits in a different clinical context that has never been bridged by a comparator-arm study: sermorelin's pivotal data are pediatric (the Geref approval-era trials in children with idiopathic growth-hormone deficiency, supporting NDA 20-443), while tesamorelin's pivotal data are adult and HIV-specific (the Phase III LIPO-010 and pooled LIPO-011 program in HIV-associated lipodystrophy, n≈816, with CT-measured visceral adipose tissue reduction as the primary endpoint and a 52-week extension confirming durability during continued treatment). Both compounds are placed within the same mechanistic class — GHRH-receptor agonists that mimic native GHRH and act synergistically with the endogenous GH axis — in narrative reviews of growth-hormone secretagogues, but those reviews treat the two as related rather than competing entries. A retrospective summary of sermorelin as an adult-GHD option similarly frames the molecule against recombinant GH and other GHRH analogs without contributing direct comparative outcome data (Walker 2006; Prakash 1999).

Safety profile comparison

The two safety profiles share a class signature inherited from GHRH-receptor activation and downstream GH/IGF-1 elevation. Both peptides report injection-site reactions (erythema, pruritus, induration), facial flushing or vasomotor symptoms, and the metabolic consequences of stimulating the somatotroph axis. Beyond that common floor, the documented profiles differ in granularity, reflecting the difference in the size and rigor of the clinical evidence base. Sermorelin's documented safety signals come predominantly from the historical Geref pediatric label era and include injection-site reactions, transient facial flushing, headache, dizziness, and altered sense of taste, together with labeling-era cautions in untreated hypothyroidism, epilepsy, obesity, and hyperglycemia (Prakash 1999); long-term safety in healthy or aging adults at compounding-era off-label exposure is not characterized in controlled studies. Tesamorelin's safety profile is anchored in the Phase III HIV-lipodystrophy program and the current Egrifta prescribing information: arthralgia and myalgia, peripheral edema (fluid retention), glucose intolerance and HbA1c elevation (GH antagonizes insulin action), supraphysiological IGF-1 elevation as an expected pharmacodynamic effect with theoretical chronic-elevation concerns, carpal tunnel-like paresthesias as a class effect of GH/IGF-1 activation, and rare hypersensitivity reactions including anaphylaxis. The Egrifta label explicitly states that long-term cardiovascular safety is not known; a mandated long-term post-marketing cohort study tracking MACE, malignancy, type 2 diabetes, and retinopathy in the HIV-lipodystrophy population is ongoing. Active malignancy and disrupted hypothalamic-pituitary axis are contraindicated per the tesamorelin label. Pregnancy is contraindicated for tesamorelin; sermorelin was historically Pregnancy Category C on the withdrawn Geref label. Neither product currently carries a boxed warning unique to itself in the available regulatory record.

Indication overview

Sermorelin's historical FDA approvals were for diagnosis of pituitary GH reserve (Geref Diagnostic, NDA 19-863, 1990) and treatment of pediatric idiopathic growth-hormone deficiency (Geref, NDA 20-443, 1997); no active US FDA approval for sermorelin exists as of 2026, and its present US availability is restricted to off-label compounding-pharmacy prescriptions, primarily for adult body-composition, sleep, and anti-aging indications for which dedicated controlled efficacy trials have not been performed (Walker 2006). Tesamorelin is FDA-approved for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy under the Egrifta, Egrifta SV, and Egrifta WR formulations, with the most recent reformulation (Egrifta WR) approved in March 2025. The Egrifta label explicitly states that the product is not indicated for weight-loss management. EMA marketing authorization for tesamorelin was withdrawn by the sponsor, while Health Canada approval remains. Both peptides are classified as Prohibited at all times by WADA under category S2; prior or present FDA approval does not exempt either compound from this classification, and a Therapeutic Use Exemption process exists for athletes with documented medical need. Within the broader peptide therapeutics literature, both molecules are increasingly discussed alongside other growth-hormone secretagogues used in adjunctive contexts such as orthopedic tissue regeneration and metabolic management (Sinha 2020; Rahman 2026), though these mentions describe class-level mechanistic rationale rather than approved indications for either specific compound.